Cure8 research brief
For people with moderate–severe Crohn’s disease who failed anti‑TNF drugs, this trial suggests risankizumab may achieve higher corticosteroid‑free clinical and endoscopic remission than ustekinumab, which could mean fewer steroid‑related side effects and better disease control without ongoing steroids.
Adults with moderate–severe Crohn’s disease, especially those with prior anti‑TNF failure; clinicians choosing biologic therapy; researchers studying head‑to‑head biologic comparisons and steroid‑sparing strategies.
The analysis focuses specifically on corticosteroid‑sparing effects — patients tapered steroids starting at week 2 and outcomes measured corticosteroid‑free clinical, endoscopic, and composite endpoints through week 48.
RZB (IV induction then SC maintenance) showed statistically higher corticosteroid‑free outcomes versus UST (weight‑based IV induction then SC maintenance) in this trial population. Safety signals mentioned were exposure‑adjusted rates of serious infections and hypersensitivity, especially in the context of concomitant steroid use.
These results come from a randomized phase 3b trial (SEQUENCE, NCT04524611) and are presented as post hoc comparisons; the abstract-level text here reports statistical differences at predefined timepoints but does not replace personalized medical advice. Discuss treatment options, prior biologic exposure, and steroid use with your gastroenterologist.
This classification is based on the article abstract from Journal of Crohn’s & Colitis reporting post hoc results from SEQUENCE (phase 3b). Post hoc analyses can be hypothesis‑generating; confirmatory prospective analyses or full-text peer review details (subgroup definitions, multiplicity adjustment, and safety event adjudication) are important for interpretation.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: AbbVie
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study suggests risankizumab may improve quality of life and reduce common symptoms (fatigue, mood, urgency) more than ustekinumab for patients with moderate-to-severe Crohn’s disease who didn’t respond to anti-TNF...
IL‑23 inhibitors are an important and growing class of drugs for Crohn’s disease. Comparing them helps patients and clinicians understand differences in trial results, approvals, and possible treatment choices.
This study reports real-world effectiveness of risankizumab for refractory Crohn's disease, showing many patients achieved steroid-free remission. The results are relevant for people weighing treatment options after...
